tiprankstipranks
Advertisement
Advertisement

IPHA Stock Latest News

Innate Pharma: Buy Rating Reaffirmed on Pipeline Momentum and De‑Risking Catalysts; $8 Price Target Unchanged
RatingsInnate Pharma: Buy Rating Reaffirmed on Pipeline Momentum and De‑Risking Catalysts; $8 Price Target Unchanged
12d ago
IPHA
Innate Pharma: Underappreciated Topo‑I ADC Pipeline and Differentiated IPH4502 Support Buy Rating
PremiumRatings
Innate Pharma: Underappreciated Topo‑I ADC Pipeline and Differentiated IPH4502 Support Buy Rating
2M ago
IPHA
Innate Pharma assumed with a Buy at BTIG
PremiumThe Fly
Innate Pharma assumed with a Buy at BTIG
3M ago
IPHA
Innate Pharma: Diversified Oncology Pipeline and AstraZeneca Partnership Create Compelling Upside Ahead of 2026 Inflection Points
PremiumRatings
Innate Pharma: Diversified Oncology Pipeline and AstraZeneca Partnership Create Compelling Upside Ahead of 2026 Inflection Points
3M ago
IPHA
Innate Pharma announces FDA clearance to proceed with TELLOMAK 3 trial
PremiumThe Fly
Innate Pharma announces FDA clearance to proceed with TELLOMAK 3 trial
7M ago
IPHA
Innate Pharma upgraded to Buy from Neutral at H.C. Wainwright
PremiumThe FlyInnate Pharma upgraded to Buy from Neutral at H.C. Wainwright
7M ago
IPHA
Innate Pharma initiated with a Buy at Lucid Capital
Premium
The Fly
Innate Pharma initiated with a Buy at Lucid Capital
7M ago
IPHA
Innate Pharma management to meet with BTIG
Premium
The Fly
Innate Pharma management to meet with BTIG
8M ago
IPHA
Innate Pharma management to meet with BTIG
PremiumThe Fly
Innate Pharma management to meet with BTIG
8M ago
IPHA
Target initiated, Nike upgraded: Wall Street’s top analyst calls
PremiumThe Fly
Target initiated, Nike upgraded: Wall Street’s top analyst calls
8M ago
DG
HD
Innate Pharma downgraded to Neutral from Buy at H.C. Wainwright
PremiumThe Fly
Innate Pharma downgraded to Neutral from Buy at H.C. Wainwright
8M ago
IPHA
Innate Pharma SA Reports First Half 2025 Financial Results
PremiumCompany Announcements
Innate Pharma SA Reports First Half 2025 Financial Results
8M ago
IPHA
Innate Pharma’s Strategic Shift and Financial Challenges Lead to Hold Rating
PremiumRatingsInnate Pharma’s Strategic Shift and Financial Challenges Lead to Hold Rating
8M ago
IPHA
Innate Pharma downgraded to Market Perform from Outperform at Leerink
Premium
The Fly
Innate Pharma downgraded to Market Perform from Outperform at Leerink
8M ago
IPHA
Innate Pharma initiated with a Buy at BTIG
Premium
The Fly
Innate Pharma initiated with a Buy at BTIG
10M ago
IPHA
PremiumCompany Announcements
Innate Pharma’s IPH4502 Study: A New Hope in Cancer Treatment
10M ago
IPHA
Innate Pharma presents preclinical data for IPH6501 at EHA
PremiumThe Fly
Innate Pharma presents preclinical data for IPH6501 at EHA
12M ago
IPHA
Innate Pharma presents long-term follow-up data from TELLOMAK trial
PremiumThe Fly
Innate Pharma presents long-term follow-up data from TELLOMAK trial
1y ago
IPHA
Innate Pharma: Navigating Challenges with Promising Pipeline and Strategic Partnerships
PremiumRatings
Innate Pharma: Navigating Challenges with Promising Pipeline and Strategic Partnerships
1y ago
IPHA
Innate Pharma price target lowered to $11 from $11.50 at H.C. Wainwright
PremiumThe FlyInnate Pharma price target lowered to $11 from $11.50 at H.C. Wainwright
1y ago
IPHA
Innate Pharma announces EUR 15M capital increase from Sanofi
Premium
The Fly
Innate Pharma announces EUR 15M capital increase from Sanofi
1y ago
SNY
IPHA
Innate Pharma regains rights to Anket, announces potential Sanofi investment
Premium
The Fly
Innate Pharma regains rights to Anket, announces potential Sanofi investment
1y ago
SNY
IPHA

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >